Interestingly, elevated concentrations of soluble FKN in plasma before starting immunotherapies was associated with high systemic myeloid cell diversity, increased monocyte populations, and prolonged survival in NSCLC patients [67]. The gene discussed is CX3CL1; the disease is non-small cell lung carcinoma.